Abbott Acquires Walk Vascular

September 2, 2021—Abbott announced that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots.

According to Abbott’s press release, Walk Vascular’s Jeti peripheral thrombectomy system and next-generation Jeti AIO all-in-one peripheral thrombectomy system are aspiration systems designed to break up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots.

Both Jeti peripheral thrombectomy systems have received FDA 510(k) clearance for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark approval in Europe and approvals in other countries.

The press release noted that the Jeti systems are backed by real-world clinical experiences. Additionally, Walk Vascular is currently enrolling up to 250 patients in the United States and Europe in the JETi Registry.

Abbott stated that Walk Vascular’s peripheral thrombectomy systems will be incorporated into its existing endovascular product portfolio. Financial terms were not disclosed.

Julie Tyler, senior vice president of Abbott’s vascular business, commented in the company’s announcement, “The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care. Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”